Chimerix (NASDAQ:CMRX) Stock Rating Upgraded by ValuEngine

ValuEngine upgraded shares of Chimerix (NASDAQ:CMRX) from a strong sell rating to a sell rating in a report issued on Wednesday, May 2nd.

Several other research analysts have also issued reports on CMRX. Zacks Investment Research lowered Chimerix from a hold rating to a sell rating in a research report on Tuesday, January 9th. HC Wainwright initiated coverage on Chimerix in a research report on Friday, February 2nd. They issued a buy rating and a $10.00 price target on the stock. JPMorgan Chase lowered Chimerix from a neutral rating to an underweight rating in a research report on Wednesday, February 14th. Cowen reaffirmed a hold rating and set a $6.00 price objective on shares of Chimerix in a research note on Thursday, March 1st. Finally, BidaskClub raised Chimerix from a hold rating to a buy rating in a research note on Friday, March 9th. Two analysts have rated the stock with a sell rating, two have given a hold rating, one has given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus target price of $7.08.

Shares of Chimerix traded up $0.11, hitting $4.86, during midday trading on Wednesday, MarketBeat.com reports. The company had a trading volume of 170,200 shares, compared to its average volume of 188,617. Chimerix has a 12 month low of $4.73 and a 12 month high of $4.81. The firm has a market capitalization of $221.57 million, a P/E ratio of -3.22 and a beta of 1.26.

Chimerix (NASDAQ:CMRX) last posted its quarterly earnings results on Monday, May 7th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.43) by $0.01. Chimerix had a negative return on equity of 31.97% and a negative net margin of 1,736.95%. The business had revenue of $0.79 million for the quarter, compared to analyst estimates of $1.12 million. sell-side analysts predict that Chimerix will post -1.77 earnings per share for the current year.

In related news, Director Ernest Mario sold 52,553 shares of the firm’s stock in a transaction on Monday, May 14th. The stock was sold at an average price of $4.64, for a total transaction of $243,845.92. Following the sale, the director now owns 12,905 shares of the company’s stock, valued at approximately $59,879.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 12.50% of the company’s stock.

A number of institutional investors have recently modified their holdings of CMRX. Prosight Management LP acquired a new stake in Chimerix during the 4th quarter worth $6,846,000. ArrowMark Colorado Holdings LLC raised its stake in shares of Chimerix by 58.3% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 2,707,986 shares of the biopharmaceutical company’s stock valued at $12,538,000 after purchasing an additional 996,936 shares during the period. BlackRock Inc. raised its stake in shares of Chimerix by 20.7% in the 4th quarter. BlackRock Inc. now owns 3,530,729 shares of the biopharmaceutical company’s stock valued at $16,348,000 after purchasing an additional 605,075 shares during the period. Ascend Capital LLC raised its stake in shares of Chimerix by 96.9% in the 4th quarter. Ascend Capital LLC now owns 699,664 shares of the biopharmaceutical company’s stock valued at $3,240,000 after purchasing an additional 344,311 shares during the period. Finally, Dimensional Fund Advisors LP raised its stake in shares of Chimerix by 19.3% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,728,095 shares of the biopharmaceutical company’s stock valued at $9,072,000 after purchasing an additional 279,845 shares during the period. 74.73% of the stock is currently owned by institutional investors and hedge funds.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply